Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) has shared an update.
Shin Nippon Biomedical Laboratories, Ltd. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing a significant increase in net sales by 22.5% to ¥32,413 million. However, the company experienced a decline in operating profit by 28.3% and ordinary profit by 8.1%, indicating challenges in maintaining profitability despite revenue growth. The financial results highlight a strategic focus on increasing sales while managing operational efficiencies, impacting stakeholders’ expectations and the company’s market positioning.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates in the biomedical research industry, focusing on providing preclinical and clinical research services. The company is listed on the Prime Market of the Tokyo Stock Exchange and is known for its contributions to drug development and safety testing.
Average Trading Volume: 363,632
Technical Sentiment Signal: Buy
Current Market Cap: Yen64.65B
For detailed information about 2395 stock, go to TipRanks’ Stock Analysis page.